Sweden
· Delayed Price · Currency is SEK Dextech Medical AB Company Description
Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer.
Its principal product candidate is OsteoDex that has completed phase IIb clinical trial for the treatment of skeletal metastases in castration resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma.
The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, to treat acromegaly, neuroendocrine tumors, and palliative treatment for advanced prostate cancer; and PSMA-binding conjugates for the target-specific treatment of mCRPC that overexpresses prostate specific membrane antigen (PSMA).
In addition, the company offers GuaDex (formarly CatDex), a technology platform and a charge-modified dextran molecule with tumor-toxic properties used for medication development.
Dextech Medical AB was incorporated in 2004 and is based in Uppsala, Sweden.
| Country | Sweden |
| Founded | 2004 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 1 |
| CEO | Anders Holmberg |
Contact Details
Address: Dag HammarskjOelds VAeg 34A Uppsala, 752 37 Sweden | |
| Phone | 46 7 07 10 47 88 |
| Website | dextechmedical.com |
Stock Details
| Ticker Symbol | DEX |
| Exchange | Nordic Growth Market |
| Fiscal Year | July - June |
| Reporting Currency | SEK |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Anders Holmberg | Chief Executive Officer |
| Gösta Lundgren | Chief Financial Officer |
| Gösta Lundgren | Head of Investor Relations |